Skip to main content
SpringerLink
Log in

Estro-progestinici in menopausa: benefici e rischi

  • Published:
L’Endocrinologo Aims and scope

Riassunto

Il rapporto rischi/benefici della terapia ormonale sostitutiva (HRT: hormone replacement therapy) non può essere definito in assoluto. La selezione delle donne, il timing di inizio, la durata e il tipo della terapia stessa condizionano la risposta clinica in maniera determinante. Non esiste un unico schema terapeutico migliore di altri in assoluto. La variabile risposta terapeutica è estremamente individuale e impone la profonda conoscenza di diverse preparazioni. I numerosi preparati di HRT a basse dosi consentono un controllo adeguato della sintomatologia e della perdita di massa ossea, minimizzando effetti collaterali e possibili rischi.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Bibliografia

  1. Genazzani AR, Gambacciani M, International Menopause Society. Controversial issues in climacteric medicine I. Cardiovascular disease and hormone replacement therapy. International Menopause Society Expert Workshop. 13–16 October 2000, Royal Society of Medicine, London, UK. Climacteric 3: 233, 2000.

    Article  CAS  PubMed  Google Scholar 

  2. Genazzani AR, Gadducci A, Gambacciani M. Controversial issues in climacteric medicine II. Hormone replacement therapy and cancer. International Menopause Society Expert Workshop. 9–12 June 2001, Opera del Duomo, Pisa, Italy. Climacteric 4: 181, 2001.

    Article  CAS  PubMed  Google Scholar 

  3. Genazzani AR, Gambacciani M, Simoncini T, Schneider HP. Controversial issues in climacteric medicine III: Hormone replacement therapy in climacteric and aging brain. Climacteric 6: 188, 2003.

    Article  CAS  PubMed  Google Scholar 

  4. Gambacciani M, Monteleone P, Sacco A, Genazzani AR. Hormone replacement therapy and endometrial, ovarian and colorectal cancer. Best Pract Res Clin Endocrinol Metab 17: 139, 2003.

    Article  CAS  PubMed  Google Scholar 

  5. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 280: 605, 1998.

    Article  CAS  PubMed  Google Scholar 

  6. Hulley S, Furberg C, Barrett-Connor E, Cauley J, Grady D, Haskell W, Knopp R, Lowery M, Satterfield S, Schrott H, Vittinghoff E, Hunninghake D, HERS Research Group. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 288: 58, 2002.

    Article  CAS  PubMed  Google Scholar 

  7. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J, Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288: 321, 2002.

    Article  CAS  PubMed  Google Scholar 

  8. Wassertheil-Smoller S, Anderson G, Psaty BM, Black HR, Manson J, Wong N, Francis J, Grimm R, Kotchen T, Langer R, Lasser N. Hypertension and its treatment in postmenopausal women: baseline data from the Women’s Health Initiative. Hypertension 36: 780, 2000.

    Article  CAS  PubMed  Google Scholar 

  9. Genazzani AR, Gambacciani M. A personal initiative for women’s health: to challenge the Women’s Health Initiative. Gynecol Endocrinol 16: 255, 2002.

    Article  CAS  PubMed  Google Scholar 

  10. Gambacciani M, Rosano GM, Monteleone P, Fini M, Genazzani AR. Clinical relevance of the HERS trial. Lancet 360: 64, 2002.

    Article  Google Scholar 

  11. Gambacciani M, Genazzani AR. The missing R. Gynecol Endocrinol 17: 91, 2003.

    Article  CAS  PubMed  Google Scholar 

  12. Naftolin F, Taylor HS, Karas R. Early initiation of hormone therapy and clinical cardioprotection: the Women’s Health Initiative (WHI) could not have detected cardioprotective effects of starting hormone therapy during the menopausal transition. Fertil Steril 81: 1498, 2004.

    Article  PubMed  Google Scholar 

  13. Karas RH, Clarkson TB. Considerations in interpreting the cardiovascular effects of hormone replacement therapy observed in the WHI: timing is everything. Menopausal Med 10: 8, 2003.

    Google Scholar 

  14. Lobo RA. Evaluation of cardiovascular event rates with hormone therapy in healthy, early postmenopausal women. Results from 2 large clinical trials. Arch Intern Med 164: 482, 2004.

    Article  PubMed  Google Scholar 

  15. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, Trevisan M, Black HR, Heckbert SR, Detrano R, Strickland OL, Wong ND, Crouse JR, Stein E, Cushman M. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 349: 523, 2003.

    Article  CAS  PubMed  Google Scholar 

  16. Salpeter SR, Walsh JM, Greyber E, Ormiston TM, Salpeter EE. Mortality associated with hormone replacement therapy in younger and older women: a meta-analysis. J Gen Intern Med 19: 791, 2004.

    Article  PubMed Central  PubMed  Google Scholar 

  17. Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB, Ockene JK, Hendrix SL, Jones BN 3rd, Assaf AR, Jackson RD, Kotchen JM, Wassertheil-Smoller S, Wactawski-Wende J, WHIMS Investigators. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women’s Health Initiative Memory Study: a randomized controlled trial. JAMA 289: 2651, 2003.

    Article  CAS  PubMed  Google Scholar 

  18. Bush TL, Whiteman M, Flaws JA. Hormone replacement therapy and breast cancer: a qualitative review. Obstet Gynecol 98: 498, 2001.

    Article  CAS  PubMed  Google Scholar 

  19. Gambacciani M, Genazzani AR. The study with a million women (and hopefully fewer mistakes). Gynecol Endocrinol 17: 359, 2003.

    Article  CAS  PubMed  Google Scholar 

  20. Beral V, Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362: 419, 2003.

    Article  CAS  PubMed  Google Scholar 

  21. de Lignieres B, de Vathaire F, Fournier S, Urbinelli R, Allaert F, Le MG, Kuttenn F. Combined hormone replacement therapy and risk of breast cancer in a French cohort study of 3175 women. Climacteric 5: 332, 2002.

    Article  PubMed  Google Scholar 

  22. Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, Rodabough RJ, Gilligan MA, Cyr MG, Thomson CA, Khandekar J, Petrovitch H, McTiernan A, WHI Investigators. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women’s Health Initiative Randomized Trial. JAMA 289: 3243, 2003.

    Article  CAS  PubMed  Google Scholar 

  23. The Women’s Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women’s Health Initiative randomized controlled trial. JAMA 291: 1701, 2004.

    Article  Google Scholar 

  24. Chlebowski RT, Wactawski-Wende J, Ritenbaugh C, Hubbell FA, Ascensao J, Rodabough RJ, Rosenberg CA, Taylor VM, Harris R, Chen C, Adams-Campbell LL, White E, Women’s Health Initiative Investigators. Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med 350: 991, 2004.

    Article  CAS  PubMed  Google Scholar 

  25. Cauley JA, Robbins J, Chen Z, Cummings SR, Jackson RD, LaCroix AZ, LeBoff M, Lewis CE, McGowan J, Neuner J, Pettinger M, Stefanick ML, Wactawski-Wende J, Watts NB, Women’s Health Initiative Investigators. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women’s Health Initiative randomized trial. JAMA 290: 1729, 2003.

    Article  CAS  PubMed  Google Scholar 

  26. Bagger YZ, Tanko LB, Alexandersen P, Hansen HB, Mollgaard A, Ravn P, Qvist P, Kanis JA, Christiansen C. Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study. Bone 34: 728, 2004.

    Article  CAS  PubMed  Google Scholar 

  27. Gambacciani M, Ciaponi M. Postmenopausal osteoporosis management. Curr Opin Obstet Gynecol 12: 189, 2000.

    Article  CAS  PubMed  Google Scholar 

  28. Gambacciani M, Genazzani AR. Hormone replacement therapy: the benefits in tailoring the regimen and dose. Maturitas 40: 195, 2001.

    Article  CAS  PubMed  Google Scholar 

  29. Gambacciani M, Monteleone P, Genazzani AR. Low-dose hormone replacement therapy: effects on bone. Climacteric 5: 135, 2002.

    Article  CAS  PubMed  Google Scholar 

  30. Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA 287: 2668, 2002.

    Article  CAS  PubMed  Google Scholar 

  31. Gambacciani M, Ciaponi M, Cappagli B, Monteleone P, Benussi C, Bevilacqua G, Genazzani AR. Effects of low-dose, continuous combined estradiol and noretisterone acetate on menopausal quality of life in early postmenopausal women. Maturitas 44: 157, 2003.

    Article  CAS  PubMed  Google Scholar 

  32. Scarabin PY, Oger E, Plu-Bureau G, EStrogen and THrombo Embolism Risk Study Group. (ESTHER). Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 362: 428, 2003.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dipartimento di Ostetricia e Ginecologia, Centro della Menopausa, Azienda Ospedaliera Universitaria Pisana, Via Roma 67, 56100, Pisa, Italia

    Marco Gambacciani & Francesca Vacca

Authors
  1. Marco Gambacciani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Francesca Vacca
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marco Gambacciani.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gambacciani, M., Vacca, F. Estro-progestinici in menopausa: benefici e rischi. L’Endocrinologo 5, 104–110 (2004). https://doi.org/10.1007/BF03344500

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03344500

Search

Navigation